Gene Therapy for SMA-- Full technical analysis #VolatilityWatch
- RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA).
- (SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe.
- It is the number one genetic cause of death for infants.
- According to a company filling, price tag for treatment is $2.1 million.
- Product is called Zolgensma
Congrats to RGNX and Novartis for the huge accomplishment!
I am putting this on #VolatilityWatch
Come Join our Biotech trading team!
Twitter: VolatilityWatch
StockTwits: MS_Money_Moves
Disclaimer: I currently do not own any position in RGNX. This is not advice to buy or sell, It is for educational purposes. Please do your homework before investing.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.